Georgia-based healthcare firm Altoida Inc has raised $6.3 million (£5m) in a series A funding round conducted by German pharmaceutical company Merck KGaA-owned capital venture firm M Ventures, with participation from Grey Sky Venture Partners, VI Partners AG, Alpana Ventures, and FYRFLY Venture Partners.
Altoida, which is led by a team of esteemed neuroscientists, physicians and computer scientists, utilises digital biomarkers to drive better clinical outcomes for brain disease. The company will be using the raised funds to bring its FDA-cleared and CE Mark-approved medical device and brain health data platform to patients, physicians, and researchers around the globe.
Dr. Ioannis Tarnanas, PhD, Founder and Chief Scientific Officer at Altoida – an ETH University Zurich spin-off – said: “Searching for early, more accurate and scalable preclinical markers of Alzheimer’s disease has been the holy grail for clinicians, researchers and pharma companies alike that are trying to predict Alzheimer’s-type cognitive decline and develop early interventions. The ability of Altoida’s digital biomarkers platform to collect very sensitive and ecologically valid markers of early functional and cognitive changes in the most scalable way, by using only a mobile phone or tablet, is unmatched by today’s medical tests and a game changer for the field.”
Last year, market intelligence firm Tractica had predicted a rise in the global software revenue from 22 main healthcare AI use cases to $8.6bn (£7bn) per year by 2025 and the total revenue for healthcare AI market, including sales from healthcare AI software, hardware, and services, to exceed £27bn by 2025.
Attend the co-located AI & Big Data Expo events with upcoming shows in Silicon Valley, London and Amsterdam to learn more. Co-located with the , and Cyber Security &
